SANFORD-BURNHAM MEDICAL RES INSTITUTE has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2011. It filed its patents most often in EPO (European Patent Office), United States and Canada. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are TSRL INC, ALKERMES PHARMA IRELAND LTD and SHANGHAI INST MATERIA MEDICA CAS.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | United States | 3 | |
#3 | Canada | 2 | |
#4 | China | 1 | |
#5 | Japan | 1 | |
#6 | WIPO (World Intellectual Property Organization) | 1 | |
#7 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Audio-visual technology | |
#5 | Optics | |
#6 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Maloney Patrick | 2 |
#2 | Hershberger Paul | 2 |
#3 | Pinkerton Anthony B | 2 |
#4 | Peddibhotla Satyamaheshwar | 2 |
#5 | Hershberger Paul M | 1 |
#6 | Marintha L Heil | 1 |
#7 | Nicholas D P Cosford | 1 |
#8 | Jeffrey H Price | 1 |
#9 | Vamos Mitchell Dennis | 1 |
#10 | Teriete Peter | 1 |
Publication | Filing date | Title |
---|---|---|
WO2016176473A1 | Apelin receptor agonists and methods of use thereof | |
EP3160961A2 | Small molecule agonists of neurotensin receptor 1 | |
US2015329497A1 | Small molecule agonists of neurotensin receptor 1 | |
CN107050007A | It is related to the method and composition of Retinoid receptor selective channel |